What diseases does Ruxolitinib treat?

Ruxolitinib tablets (Ruxolitinib) were first approved by the U.S. Food and Drug Administration (FDA) in 2011 for the treatment of moderate or high-risk myelofibrosis (MF), including adults with primary MF, post-polycythemia vera MF and post-idiopathic thrombocythemia MF. is also suitable for parahydroxy- For the treatment of polycythemia vera (PV) in adults with poor response to or intolerance to urea, it is also indicated for the treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older and for the treatment of chronic graft-versus-host disease (cGVHD) in adult and pediatric patients 12 years and older after failure of one or two systemic therapies.